The increasing use of high-cost medicines is the primary cost driver for all Canadian drug plans, according to a new report by the Patented Medicine Prices Review Board. It found drug costs for public plans rose by 5.3 per cent in 2019/20, with high-cost medicines accounting for 6.3 per cent of the increase. Among private […]
Amid the increasing introduction of specialized medicines in Canada, key stakeholders in the private payer health-care sector are enhancing their collaborations to maintain the value of private drug coverage, said Joe Farago, executive director of private payers and investment at Innovative Medicines Canada, during a webinar by the Group Insurance Pharmaceutical Committee this week. “[The […]
There’s no question that Canadians value their private health benefits, even with pharmacare discussions back on the table. In a recent Abacus Data study, 78 per cent of respondents said they feel group benefits plans increase the availability and affordability of health services in Canada, as opposed to undermining universal health coverage. Furthermore, 92 per […]
Severe asthma is a complex condition that impacts between 150,000 and 250,000 Canadians, according to Vanessa Foran, president and chief executive officer of Asthma Canada, during a webinar hosted last month by Benefits Canada and supported by AstraZeneca. It’s an acute condition where people have difficulty achieving control of their disease despite proper use of […]
The amendments to the Patented Medicine Prices Review Board regulations are officially taking effect July 1, after being delayed multiple times. The changes, which were originally proposed in 2019, are the first significant update to the regulations in more than 30 years. After consulting with stakeholders, Health Canada will be moving forward with the implementation of […]
Benefits Canada is extending the deadline for entering the 2022 Workplace Benefits Awards to Friday, July 8 at 5 p.m. EST. The annual awards recognize employers and plan sponsors that are leading the way with their approaches to supporting the mental, physical and financial well-being of their employees. Enter the 2022 Workplace Benefits Awards today. This year’s […]
As the coronavirus pandemic continues, fewer Canadian benefits plan members are making drug claims, according to Telus Health’s annual drug trends report. The report, based on the drug claims activity of more than 10 million plan members in 2021, found just 56 per cent made a claim in 2021, reflecting a decreased frequency of in-person […]
While medications used for treating inflammatory disease accounted for just 0.7 per cent of claims across Telus Health’s Canadian block of business in 2021, they represent the largest percentage of eligible drug costs at 12.6 per cent, due to the prevalence of high-cost treatments in this drug class. By comparison, diabetes medications accounted for 12 […]
The Federal Trade Commission is launching an inquiry into the operations of pharmacy benefits managers that control access to prescription drugs for millions of Americans. The consumer protection agency will order the nation’s largest PBMs to provide a range of information and records detailing how they do business. Pharmacy benefits managers run prescription drug coverage […]
A British Columbia labour arbitration decision is providing insight on how a block level implementation of a benefits provider’s drug cost-control program violated a collective agreement in a unionized workplace. The Douglas College Faculty Association grieved the implementation of Manulife’s DrugWatch program contravened their collective agreement, which ensured “there will be no change to the […]